Opinion
Video
Author(s):
Experts on prostate cancer discuss how treatment has evolved over the years, focusing on doublet and triplet therapy and their utility.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
FDA updates in urology: May 2025
Dr. Murphy on increasing diversity in cancer clinical trials
Phase 2 trial launches of combination immunotherapy for mCRPC
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Long-term data support radium-223 safety in mCRPC
Survey: New NMIBC treatments face slow uptake